CG Oncology, Inc. (CGON) stock
CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$80.00+1.06 (+1.34%)
Close on Nov 18, 2026Market cap $7.09BP/E –Yield –
CG Oncology operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
CG Oncology's operating income for the twelve months ending Sep 30, 2026 was -$264.74M. For fiscal 2025 it was -$190.77M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$190.77M | – |
| FY2024 | Dec 31, 2024 | -$114.67M | – |
| FY2023 | Dec 31, 2023 | -$55.45M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$63.25M | – |
| Q2 FY2026 | Jun 30, 2026 | -$86.40M | – |
| Q1 FY2026 | Mar 31, 2026 | -$66.39M | – |
| Q4 FY2025 | Dec 31, 2025 | -$48.70M | – |
| Q3 FY2025 | Sep 30, 2025 | -$51.13M | – |
| Q2 FY2025 | Jun 30, 2025 | -$48.74M | – |
| Q1 FY2025 | Mar 31, 2025 | -$42.20M | – |
| Q4 FY2024 | Dec 31, 2024 | -$38.05M | – |
| Q3 FY2024 | Sep 30, 2024 | -$28.30M | – |
| Q2 FY2024 | Jun 30, 2024 | -$25.85M | – |
| Q1 FY2024 | Mar 31, 2024 | -$22.47M | – |
| Q4 FY2023 | Dec 31, 2023 | -$19.36M | – |
| Q3 FY2023 | Sep 30, 2023 | -$14.04M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.33M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.72M | – |
See a number that looks wrong?